Novo Nordisks next big weight-loss hopeful is stacking up evidence. New June diabetes data for CagriSema arrived ahead of an FDA obesity decision expected later in 2026.
In June 2026, Novo Nordisk reported new type 2 diabetes data (the REIMAGINE program) for CagriSema, its combination of semaglutide and cagrilintide, ahead of an FDA decision on the obesity indication expected later in 2026. In obesity trials (REDEFINE-1), CagriSema produced about 20.4 percent average weight loss. It is not yet FDA-approved.
Among the next wave of weight-loss drugs, Novo Nordisks CagriSema is the furthest along toward approval.
June brought fresh data as the company awaits a key FDA decision.
In mid-June 2026, coverage highlighted new type 2 diabetes results for CagriSema, Novo Nordisks once-weekly injectable combining semaglutide (the active ingredient in Ozempic and Wegovy) with cagrilintide, an amylin-pathway agent. The REIMAGINE diabetes program reported improved blood-sugar control, adding clinical evidence as the company awaits an FDA decision on the obesity indication, widely expected later in 2026, with a potential launch by early 2027 if approved.
On the obesity side, CagriSema is supported by the REDEFINE trial program; in the pivotal REDEFINE-1 trial it produced about 20.4 percent average weight loss over 68 weeks, more than semaglutide alone but, in reported comparisons, not exceeding tirzepatide. Novo Nordisk filed its US application for weight management in December 2025. As of June 2026, CagriSema remained investigational and not FDA-approved.
For consumers, CagriSema represents another potentially strong option in a fast-growing class, but it is not yet available, and trial averages are not individual guarantees. Its combination mechanism may offer benefits for some, while comparisons with existing drugs remain nuanced. The meaningful milestone is the FDA decision, after which any use would be an individualized clinical choice made with a prescriber, weighed against other approved options.
Watch for the FDA decision on CagriSemas obesity indication expected later in 2026, plus any additional efficacy, tolerability, and manufacturing details. How it is positioned relative to tirzepatide and the oral options will matter for access. For individuals, the practical posture is to follow approval rather than trial buzz, and to discuss the best current, approved option with a prescriber based on personal goals and health.